OnKure Therapeutics, Inc.

NASDAQ:OKUR

Biotechnology

Healthcare
$2.82 +0.23%

+$0.01 today

Market cap
$114.22M
Beta
0.28
P/E (TTM)
-1.0
EPS (TTM)
-$4.30
52W Low $1.91High $5.38

Volume 0.17M

Average 0.37M

OKUR Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

OnKure Therapeutics, Inc.NASDAQ: OKUR

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures declines year over year

Q1 FY2026 capital expenditures of $5K (cash outflow) fell 72.2% year over year, behind the -65.6% change in trailing-twelve-month capital expenditures. Sequentially, it fell 44.4% from the prior quarter. Over 3 fiscal years it compounded at -65.6% a year.

Context

  • Capital expenditures grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -72.2% toward the trailing-twelve-month pace of -65.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$5K-44.4% QoQ
Last fiscal yearDec 2025
-$46K-11.5% YoY
LTMMar 2026
-$33K-65.6% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-72.2%——
1 year-11.5%——
3-year CAGR-65.6%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(46K) USD
Year-over-year change
+11.5%

Capital Expenditures vs competitors

How OKUR compares with its peers on the latest reported figures

  • OKUR's LTM Mar 2026 capital expenditures of $33K is the 3rd largest of the 4 companies compared; the peer median is $584K.
  • Its year-over-year change of -65.6% is the lowest of 3, against a peer median of +906.9%.
  • Over three fiscal years its annual growth of -65.6% compares with a peer median of -34.5%.
OKUR Competitors Peer median
Capital Expenditures for OKUR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XLOXilio Therapeutics, Inc.LTM Mar 2026$1.05M +1713.8%-34.8%2.0%
ATNMActinium Pharmaceuticals, Inc.LTM Jun 2026$584K —-34.3%1.7%
OKUROnKure Therapeutics, Inc.LTM Mar 2026$33K -65.6%-65.6%—
PDSBPDS Biotechnology CorporationLTM Mar 2026$4 +100.0%——
Peer median (excluding OKUR) $584K+906.9%-34.5%1.8%

Competitors are the stored peer set for OKUR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(39.77M)(29.51M)(35.31M)(52.67M)(59.52M)
Depreciation & Amortization50K387K560K662K830K
Deferred Income Tax00000
Stock-Based Compensation048K199K4.53M11.63M
Change in Working Capital(2.8M)2.12M6K(3.95M)(4.78M)
Accounts Receivables00000
Inventory00000
Accounts Payables001.71M(5.93M)(4.55M)
Other Working Capital(2.8M)2.12M(1.71M)1.98M(235K)
Other Non-Cash Items4.54M00316K6K
Operating Cash Flow(37.98M)(26.95M)(34.55M)(51.12M)(51.83M)
Capital Expenditures(198K)(1.13M)(246K)(52K)(46K)
Acquisitions (Net)00000
Purchases of Investments(31.41M)0000
Sales of Investments8.23M44.1M015.93M0
Other Investing Activities0(44.1M)000
Investing Cash Flow(23.38M)(1.13M)(246K)15.87M(46K)
Debt Repayment0006M0
Common Stock Issued132.41M340K65K58.91M203K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(1.38M)(723K)51.22M(40K)
Financing Cash Flow132.41M26.47M53.13M116.13M163K
Effect of Forex Changes00000
Net Change in Cash71.05M(1.62M)18.33M80.89M(51.71M)
Free Cash Flow(38.18M)(28.09M)(34.79M)(51.17M)(51.87M)

OnKure Therapeutics, Inc.

NASDAQ:OKUR

Intrinsic Alpha fair value

Locked

Current Price

$2.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.